{"schema_version":"secwatch.filing_event.v1","accession":"0000096943-25-000112","form_type":"8-K","ticker":"TFX","cik":"0000096943","company_name":"TELEFLEX INC","filed_at":"2025-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.786614+00:00","generated_at":"2026-05-17T22:43:10.139580+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Teleflex Q2 adj. EPS $3.73 beats $3.42 YoY; raises FY outlook on BIOTRONIK deal","bullets":["GAAP revenue $780.9M (+4.2% YoY); adjusted constant currency revenue growth +1.0%.","GAAP diluted EPS $2.77 vs $1.69; adjusted diluted EPS $3.73 vs $3.42.","Full-year GAAP revenue growth guidance raised to 9.0%-10.0% (from 1.3%-2.3%) due to BIOTRONIK acquisition.","FY adjusted diluted EPS guidance raised to $13.90-$14.30 from $13.20-$13.60.","Interventional segment revenue surged 20.4% as reported; OEM and Interventional Urology each declined over 8%."],"urls":{"canonical":"https://secwatch.observer/filing/0000096943-25-000112","json":"https://secwatch.observer/filing/0000096943-25-000112.json","markdown":"https://secwatch.observer/filing/0000096943-25-000112.md","text":"https://secwatch.observer/filing/0000096943-25-000112.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/96943/000009694325000112/0000096943-25-000112-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/96943/000009694325000112/tfx-20250731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T22:43:10.139580+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}